Development and validation of the Aortic valve Stenosis Guarded by Amplified Risk Determination (ASGARD) risk score for safe monitoring in asymptomatic non-severe aortic valve stenosis

Author:

Hadziselimovic Edina1ORCID,Greve Anders M2,Sajadieh Ahmad13ORCID,Olsen Michael H456,Nienaber Christoph A7,Ray Simon G8,Rossebø Anne B9,Wachtell Kristian10,Dominguez Helena13ORCID,Valeur Nana1,Carstensen Helle G1,Nielsen Olav W13

Affiliation:

1. Department of Cardiology, Bispebjerg University Hospital , Nordre Fasanvej 57, 2000 Copenhagen , Denmark

2. Department of Clinical Biochemistry 3011, Rigshospitalet , Copenhagen , Denmark

3. Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark

4. Department of Internal Medicine 1, Holbæk Hospital , Holbæk , Denmark

5. Department of Regional Health Research, University of Southern Denmark , Odense , Denmark

6. Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark

7. Royal Brompton and Harefield NHS Foundation Trust, Imperial College , London , UK

8. Manchester University Hospitals , Manchester , UK

9. Department of Cardiology, Oslo University Hospital , Ullevål , Norway

10. Division of Cardiology, Weill Cornell Medicine , New York , USA

Abstract

Abstract Aims Current guidelines recommend serial echocardiography at minimum 1–2-year intervals for monitoring patients with non-severe aortic valve stenosis (AS), which is costly and often clinically inconsequential. We aimed to develop and test whether the biomarker-based ASGARD (Aortic valve Stenosis Guarded by Amplified Risk Determination) risk score can guide the timing of echocardiograms in asymptomatic patients with non-severe AS. Methods and results The development cohort comprised 1093 of 1589 (69%) asymptomatic patients with mild-to-moderate AS who remained event-free one year after inclusion into the SEAS trial. Cox regression landmark analyses with a 2-year follow-up identified the model (ASGARD) with the lowest Akaike information criterion for association to AS-related composite outcome (heart failure hospitalization, aortic valve replacement, or cardiovascular death). Fine–Gray analyses provided cumulative event rates by ASGARD score quartiles. The ASGARD score was internally validated in the remaining 496 patients (31%) from the SEAS cohort and externally in 71 asymptomatic outpatients with non-severe AS from six Copenhagen hospitals. The ASGARD score comprises updated measurements of heart rate and age- and sex-adjusted N-terminal pro-brain natriuretic peptide upon transaortic maximal velocity (Vmax) from the previous year. The ASGARD score had high predictive accuracy across all cohorts (external validation: area under the curve: 0.74 [95% CI, 0.62–0.86]), and similar to an updated Vmax measurement. An ASGARD score ≤ 50% was associated with AS-related event rates ≤ 5% for a minimum of 15 months. Conclusion The ASGARD score could provide a personalized and safe surveillance alternative to routinely planned echocardiograms, so physicians can prioritize echocardiograms for high-risk patients.

Funder

Merck & Co., Inc.

Schering-Plough Corporation

Roche Diagnostics International Ltd

Interreg IVA

European Union

Carpenter Sophus Jacobsen and Wife Astrid Jacobsens Foundation

Publisher

Oxford University Press (OUP)

Reference40 articles.

1. Aortic stenosis;Ross;Circulation,1968

2. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines;Otto;Circulation,2021

3. 2021 ESC/EACTS Guidelines for the management of valvular heart disease;Vahanian;Eur Heart J,2021

4. Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics;Lancellotti;JAMA Cardiol,2018

5. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography;Otto;J Am Coll Cardiol,1989

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3